New combo therapy targets bone metastases in prostate cancer

NCT ID NCT03344211

Ongoing Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial studies whether adding radium-223 to enzalutamide works better than enzalutamide alone in men with castration-resistant prostate cancer that has spread to bones. Enzalutamide blocks male hormones that fuel cancer growth, while radium-223 delivers targeted radiation to bone tumors. The study involves 30 participants and will measure changes in bone involvement through biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enzalutamide and radium-223
What this could lead to: If successful, this could point toward a more effective combination treatment for men with advanced prostate cancer that has spread to the bones.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The study is also no longer recruiting, and it is unclear if the combination will improve outcomes over enzalutamide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA PROSTATE CARCINOMA METASTATIC IN THE BONE STAGE IV PROSTATE CANCER

Contacts and locations

Locations

Cedars Sinai Medical Center

Los Angeles, California, 90048, United States
City of Hope

Duarte, California, 91010, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.